Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (16)

2022

  1. IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET)

    Trials, Vol. 23, Núm. 1

  2. IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity

    Trials, Vol. 23, Núm. 1

  3. Pharmacological Probes to Validate Biomarkers for Analgesic Drug Development

    International Journal of Molecular Sciences, Vol. 23, Núm. 15

2021

  1. IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG)

    Trials, Vol. 22, Núm. 1

2019

  1. Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies

    AAPS Journal, Vol. 21, Núm. 2

2018

  1. Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer

    European Journal of Pharmaceutical Sciences, Vol. 115, pp. 296-303

  2. Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts

    Journal of Pharmacology and Experimental Therapeutics, Vol. 366, Núm. 1, pp. 96-104

2017

  1. Characterizing gemcitabine effects administered as single agent or combined with carboplatin in mice pancreatic and ovarian cancer xenografts: A semimechanistic pharmacokinetic/pharmacodynamics tumor growth-response model

    Journal of Pharmacology and Experimental Therapeutics, Vol. 360, Núm. 3, pp. 445-456

2015

  1. Can pentylenetetrazole and maximal electroshock rodent seizure models quantitatively predict antiepileptic efficacy in Humans?

    Seizure, Vol. 24, Núm. C, pp. 21-27

2014

  1. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 3, Núm. 5

2010

  1. Modelling the genesis and treatment of cancer: The potential role of physiologically based pharmacodynamics

    European Journal of Cancer, Vol. 46, Núm. 1, pp. 21-32

  2. Tailored dosing of tasisulam-sodium (LY573636-sodium) to reduce hematologic toxicity and improve therapeutic index

    EJC SUPPLEMENTS

2008

  1. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

    European Journal of Cancer, Vol. 44, Núm. 1, pp. 142-150

2007

  1. Tadalafil population pharmacokinetics in patients with erectile dysfunction

    European Journal of Clinical Pharmacology, Vol. 63, Núm. 6, pp. 583-590

2004

  1. Population dose-response model for tadalafil in the treatment of male erectile dysfunction

    Pharmaceutical Research, Vol. 21, Núm. 8, pp. 1463-1470

2000

  1. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: Application to moxonidine

    Clinical Pharmacology and Therapeutics, Vol. 68, Núm. 1, pp. 18-27